bioRxiv · 10.1101/2022.03.22.485401
Inhalable polymer nanoparticles for versatile mRNA delivery and mucosal vaccination
Abstract
An inhalable platform for mRNA therapeutics would enable minimally invasive and lung targeted delivery for a host of pulmonary diseases. Development of lung targeted mRNA therapeutics has been limited by poor transfection efficiency and risk of vehicle-induced pathology. Here we report an inhalable polymer-based vehicle for delivery of therapeutic mRNAs to the lung. We optimized biodegradable poly(amine-co-ester) polyplexes for mRNA delivery using end group modifications and polyethylene glycol. Our polyplexes achieved high transfection of mRNA throughout the lung, particularly in epithelial and antigen-presenting cells. We applied this technology to develop a mucosal vaccine for SARS-CoV-2. Intranasal vaccination with spike protein mRNA polyplexes induced potent cellular and humoral adaptive immunity and protected K18-hACE2 mice from lethal viral challenge. One-sentence summaryInhaled polymer nanoparticles (NPs) achieve high mRNA expression in the lung and induce protective immunity against SARS-CoV-2.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Suberi, A., Grun, M. K., Mao, T., Goldman-Israelow, B., Reschke, M., Grundler, J., Akhtar, L., Lee, T., Shin, K., Piotrowski-Daspit, A. S., Homer, R., Iwasaki, A., Suh, H. W., Saltzman, W. M.. 2022-03-23. Inhalable polymer nanoparticles for versatile mRNA delivery and mucosal vaccination. https://doi.org/10.1101/2022.03.22.485401
Cite the original work for its findings. Save a collection to share your selection of sources.